In the quarter, total sales fell 8% operationally, dragged down by competitive pressures in the crop business (down 19%), partially offset by steady performance in the drug group (flat sales). While we still view the crop science business as well positioned, the strong gains seen in 2022 due to less competition are reversing out and weakening current results. The steady drug group results should continue, with strong new drug launches offsetting maturing older drugs and supporting Bayer's moat. We believe recently launched cancer drug Nubeqa (up 96%) holds the potential to drive peak annual sales over EUR 3 billion. Also, kidney disease drug Kerendia should develop into another blockbuster based on a unique mechanism of action and solid efficacy data.